Livingston Group Asset Management CO operating as Southport Capital Management increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 39,460 shares of the biopharmaceutical company’s stock after acquiring an additional 686 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in Pfizer were worth $1,453,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of PFE. Northwest Wealth Management LLC grew its holdings in shares of Pfizer by 2.4% during the 3rd quarter. Northwest Wealth Management LLC now owns 11,311 shares of the biopharmaceutical company’s stock worth $415,000 after purchasing an additional 268 shares in the last quarter. HNP Capital LLC lifted its position in shares of Pfizer by 1.7% during the 3rd quarter. HNP Capital LLC now owns 16,689 shares of the biopharmaceutical company’s stock worth $607,000 after buying an additional 275 shares during the period. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC lifted its position in shares of Pfizer by 2.8% during the 3rd quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 10,195 shares of the biopharmaceutical company’s stock worth $374,000 after buying an additional 277 shares during the period. Redhawk Wealth Advisors Inc. lifted its position in shares of Pfizer by 3.7% during the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 7,710 shares of the biopharmaceutical company’s stock worth $283,000 after buying an additional 278 shares during the period. Finally, Day & Ennis LLC lifted its position in shares of Pfizer by 1.2% during the 3rd quarter. Day & Ennis LLC now owns 23,589 shares of the biopharmaceutical company’s stock worth $866,000 after buying an additional 283 shares during the period. 69.08% of the stock is currently owned by institutional investors and hedge funds.
In related news, major shareholder Pfizer Inc acquired 1,200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 27th. The stock was acquired at an average cost of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the purchase, the insider now directly owns 27,349,211 shares in the company, valued at $273,492,110. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.08% of the stock is owned by insiders.
Shares of PFE stock traded down $0.29 on Wednesday, reaching $36.89. 861,529 shares of the stock were exchanged, compared to its average volume of 36,397,031. The stock has a market cap of $205.05 billion, a PE ratio of 14.60, a P/E/G ratio of 3.10 and a beta of 0.66. Pfizer Inc. has a one year low of $27.88 and a one year high of $43.08. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16. The stock has a 50 day moving average price of $38.24 and a 200 day moving average price of $37.16.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 27th. The biopharmaceutical company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.01. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The business had revenue of $12.13 billion during the quarter, compared to analysts’ expectations of $12.30 billion. During the same period in the previous year, the firm earned $0.75 earnings per share. The firm’s quarterly revenue was down 4.3% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.84 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 5th. Investors of record on Friday, January 29th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, January 28th. This is a boost from Pfizer’s previous quarterly dividend of $0.38. This represents a $1.56 dividend on an annualized basis and a dividend yield of 4.23%. Pfizer’s payout ratio is 51.53%.
Several equities analysts have issued reports on PFE shares. Mizuho lifted their price objective on Pfizer from $43.00 to $44.00 and gave the company a “buy” rating in a research report on Tuesday, November 10th. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating and set a $37.00 price objective for the company in a research report on Thursday, October 29th. The Goldman Sachs Group set a $40.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Friday, January 8th. Atlantic Securities downgraded Pfizer from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $44.00 to $39.00 in a research report on Monday, October 12th. Finally, SVB Leerink lifted their price objective on Pfizer from $42.00 to $43.00 and gave the company a “market perform” rating in a research report on Wednesday, October 28th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $39.87.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Read More: What Does a Sell-Side Analyst Rating Mean?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.